Soy isoflavones and bone density: small pooled changes, mixed preparations
Eighteen randomized trials found modest bone-density differences after menopause, but the abstract does not establish fracture prevention.

Illustrative food image, not a photograph of the study intervention.
What the trials actually supplied
This meta-analysis examined soy isoflavones and bone mineral density in menopausal women. Researchers searched MEDLINE, EMBASE and the Cochrane Library for English-language articles published during 1995–2019 and selected 18 randomized controlled trials. The preparations were not interchangeable servings of tofu: they included genistein extracts, soy isoflavone extracts, soy protein isolate and foods containing different isoflavone amounts. That range is central to interpreting a pooled result. Although some interventions were foods, the evidence cannot be described simply as a trial of ordinary soy meals. The measured outcomes were density at the lumbar spine, femoral neck and total hip, rather than a complete assessment of bone health.
Barańska A, Kanadys W, Bogdan M, Stępień E et al.. Journal of clinical medicine, 2022. PMID 36012916 · DOI
The spine and femoral-neck estimates
Compared with controls, the pooled lumbar-spine bone-density difference was 1.63%, with a 95% confidence interval of 0.51% to 2.75%. At the femoral neck, the weighted mean difference was 1.87%, with an interval of 0.14% to 3.60%. These were statistically significant, favorable differences in the review, but the authors characterize the effects as moderate. The percentages describe pooled bone-density comparisons, not reductions in fracture rates. Keeping the anatomical sites and endpoint attached to each number avoids making the result sound more comprehensive than it was. A positive density result is the finding; fracture prevention is not an outcome established by this abstract.
Barańska A, Kanadys W, Bogdan M, Stępień E et al.. Journal of clinical medicine, 2022. PMID 36012916 · DOI
The hip result and the intervention range
For total hip bone density, the weighted mean difference was 0.39%, with a 95% confidence interval of 0.08% to 0.69%. Across studies, the reported daily isoflavone intake was 106 milligrams, with a range of 40 to 300 milligrams, and interventions lasted 6 to 24 months. These figures define the studies included in the synthesis rather than an intake target for readers. Subgroup analyses suggested that effects might vary with duration, racial diversity, time after menopause, supplement form, especially genistein, and dose. The pooled average therefore should not be treated as a result guaranteed for every preparation, participant or length of use.
Barańska A, Kanadys W, Bogdan M, Stępień E et al.. Journal of clinical medicine, 2022. PMID 36012916 · DOI
A soy recipe is not the pooled intervention
A tofu breakfast can accompany a discussion of soy research without being presented as a bone treatment. The review combined 18 trials using extracts, isolates and foods, and its abstract gives no tested serving of the linked recipe. Nor does the abstract report a fracture endpoint or establish that a density difference translates into fewer fractures. The authors conclude that soy isoflavones may slow bone loss after menopause, and their conflict statement declares no conflict of interest. The sound editorial boundary is to report the small favorable density differences while retaining the varied preparations, menopausal population and 6-to-24-month study duration that define them.
Barańska A, Kanadys W, Bogdan M, Stępień E et al.. Journal of clinical medicine, 2022. PMID 36012916 · DOI